Primary sclerosing cholangitis

DGAP-News: Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration

Retrieved on: 
Tuesday, August 16, 2022
Molecule, U.S. Securities and Exchange Commission, Regeneration, Psoriasis, Degenerative disease, USPTO, Inflammatory bowel disease, Gene, NEW, Private Securities Litigation Reform Act, SEC, Patent, Clinical trial, Security (finance), Receiver Operating Characteristic Curve Explorer and Tester, Patient, COVID-19, Multiple sclerosis, Safety, Drug development, Nature, Daiichi Sankyo, PTE, DHODH, Primary sclerosing cholangitis, Protein, Irritable bowel syndrome, Nasdaq, Diarrhea, Immune system, Metabolism, Vaccine, Pharmaceutical industry, Short course immune induction therapy

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration

Key Points: 
  • Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration
    The issuer is solely responsible for the content of this announcement.
  • In 2018, Immunic and Daiichi Sankyo entered into a global option and license agreement, granting Immunic the exclusive right to license IMU-856, which was subsequently exercised by Immunic in 2020.
  • IMU-856, which Immunic believes to be novel, is an orally available small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium.
  • IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Retrieved on: 
Tuesday, August 16, 2022
U.S. Securities and Exchange Commission, Psoriasis, Degenerative disease, USPTO, Inflammatory bowel disease, Gene, Private Securities Litigation Reform Act, SEC, Patent, Clinical trial, Security (finance), Annual report, Diarrhea, Regeneration, Patient, IMUX, COVID-19, Multiple sclerosis, Compound, Safety, Drug development, Risk, Nature, NASDAQ, Daiichi Sankyo, PTE, DHODH, Primary sclerosing cholangitis, Protein, Irritable bowel syndrome, Immune system, Metabolism, Pharmaceutical industry, Vaccine, Short course immune induction therapy

The patent application was originally filed by Daiichi Sankyo Co., Ltd. (Daiichi Sankyo), which discovered IMU-856.

Key Points: 
  • The patent application was originally filed by Daiichi Sankyo Co., Ltd. (Daiichi Sankyo), which discovered IMU-856.
  • "Allowance of this composition-of-matter patent significantly strengthens our intellectual property estate and is key to the clinical development of IMU-856, which we believe to be a highly potent small molecule oral epigenetic regulator.
  • IMU-856, which Immunic believes to be novel, is an orally available small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium.
  • IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

Retrieved on: 
Friday, August 12, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, 808, U.S. Securities and Exchange Commission, Exercise, Institute of Liver and Biliary Sciences, Equity capital markets, Primary biliary cholangitis, VISTAS, Broadridge Financial Solutions, Form, European Medicines Agency, SEC, Pregnancy, Sale, IBAT, Prospectus, Cholestatic pruritus, LLC, Security (finance), Alagille syndrome, State Street, Patient, Marketing, S-3, Acquisition, Attention, PFIC, Cholestasis, Biliary atresia, Primary sclerosing cholangitis, Medication, Nasdaq, Pharmaceutical industry, Spiroplasma mirum

The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and offering expenses, were $92.0 million.

Key Points: 
  • The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and offering expenses, were $92.0 million.
  • J.P. Morgan, SVB Securities and Evercore ISI acted as joint book-running managers for the offering.
  • Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases.
  • In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities

Retrieved on: 
Friday, August 12, 2022
Compugen, Department of Neurobiology, Harvard Medical School, Hebrew University of Jerusalem, Biomarker, CCL24, Internal medicine, Inflammation, Trial of the century, Forward-looking statement, Drug, Private Securities Litigation Reform Act, SEC, PRA Health Sciences, Parexel, Research, Communication, Department, Fibrosis, Patient, Review, Marketing, Therapy, Cirrhosis, Research and development, Doctor of Philosophy, Risk, Nature, Weizmann Institute of Science, Rhodes College, Primary sclerosing cholangitis, University, MBA, Physician, CMMB, Nasdaq, BS, Cros, Development, TEL, Pharmaceutical industry, Science, MD

TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development.

Key Points: 
  • Prior to Compugen, Dr. Vaknin served as Chief Technology Officer at Active P, where he led the development of orally available therapeutic peptides.
  • She has highly relevant experience leading clinical research programs in immuno-inflammation and orphan diseases.
  • I am delighted to welcome Ilan and Chris to the Chemomab senior team at this exciting time in our evolution."
  • Her career spans working in-house at pharmaceutical and biotechnology firms, as well as at major clinical research organizations (CROs).

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, August 11, 2022
Biotechnology, Pharmaceutical, Health, Institute of Liver and Biliary Sciences, Primary biliary cholangitis, VISTAS, European Medicines Agency, Pregnancy, IBAT, Cholestatic pruritus, Alagille syndrome, Financial compensation, Patient, Marketing, Degenerative disease, Spiroplasma mirum, PFIC, Cholestasis, Biliary atresia, Primary sclerosing cholangitis, Professional Football Compensation Committee, Medication, Employment, Nasdaq, RSU, Pharmaceutical industry

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The awards are subject to the terms and conditions of Mirums 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
  • Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases.
  • In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, U.S. Securities and Exchange Commission, Phage therapy, Saima, SEC, Clinical trial, Security (finance), Research, Bioinformatics, Cystic Fibrosis Foundation, Valencia CF Foundation, Patient, CF, International, KOL, CFF, Part, IBD, Infection, Pseudomonas aeruginosa, Acne, Conditional sentence, Partnership, Safety, Weizmann Institute of Science, Primary sclerosing cholangitis, Internet, Pharmacokinetics, Â, Mortality, Forward-looking statement, Therapy, Boehringer Ingelheim, Program, AD, Investor, Israel Innovation Authority, Organization, Biomarker, Inflammatory bowel disease, Cell, Quantification, NYSE, Psoriatic arthritis, Workforce, Company, Urinary tract infection, Cystic fibrosis, Treatment, Disease, Atopic dermatitis, Private Securities Litigation Reform Act, Colorectal cancer, Pharmaceutical industry, Risk management, Cryptocurrency

BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the second quarter ended June 30, 2022.

Key Points: 
  • BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the second quarter ended June 30, 2022.
  • Also in June, BiomX announced a second partnership with Boehringer Ingelheim to discover inflammatory bowel disease (IBD) microbiome markers.
  • Net loss for the second quarter of 2022 was $7.5 million, compared to $7.3 million for the same period in 2021.
  • BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for the second quarter 2022.

Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Wednesday, August 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, 808, U.S. Securities and Exchange Commission, Institute of Liver and Biliary Sciences, Equity capital markets, Primary biliary cholangitis, VISTAS, Broadridge Financial Solutions, Form, European Medicines Agency, SEC, Private Securities Litigation Reform Act, Pregnancy, IBAT, Prospectus, Cholestatic pruritus, Sale, LLC, Security (finance), Alagille syndrome, State Street, Patient, Marketing, COVID-19, S-3, Acquisition, Attention, PFIC, Cholestasis, Biliary atresia, Primary sclerosing cholangitis, Medication, Nasdaq, Pharmaceutical industry, Spiroplasma mirum

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced the pricing of its previously announced underwritten public offering of 3,478,261 shares of its common stock at a price to the public of $23.00 per share.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced the pricing of its previously announced underwritten public offering of 3,478,261 shares of its common stock at a price to the public of $23.00 per share.
  • The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $80.0 million.
  • In addition, Mirum has granted the underwriters a 30-day option to purchase up to an additional 521,739 shares of common stock at the public offering price less underwriting discounts and commissions.
  • The offering is expected to close on August 12, 2022, subject to satisfaction of customary closing conditions.

Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Retrieved on: 
Tuesday, August 9, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, 808, U.S. Securities and Exchange Commission, Institute of Liver and Biliary Sciences, Equity capital markets, Primary biliary cholangitis, VISTAS, Broadridge Financial Solutions, Form, European Medicines Agency, SEC, Private Securities Litigation Reform Act, Pregnancy, IBAT, Prospectus, Cholestatic pruritus, Sale, LLC, Security (finance), Alagille syndrome, State Street, Patient, Marketing, COVID-19, S-3, Spiroplasma mirum, Acquisition, Attention, PFIC, Cholestasis, Biliary atresia, Primary sclerosing cholangitis, Medication, Nasdaq, Pharmaceutical industry

In connection with the proposed offering, Mirum expects to grant the underwriters a 30-day option to purchase up to an additional approximately $12.0 million of shares of common stock.

Key Points: 
  • In connection with the proposed offering, Mirum expects to grant the underwriters a 30-day option to purchase up to an additional approximately $12.0 million of shares of common stock.
  • There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
  • J.P. Morgan, SVB Securities and Evercore ISI are acting as joint book-running managers for the proposed offering.
  • Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases.

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
GLOBE, SEC, Investment, Facebook, Integrin, Research, Annual report, Plasma protein binding, Patient, Muscular dystrophy, Fast track (FDA), Fatty liver disease, PSC, FVC, News, Idiopathic pulmonary fibrosis, QLF, Food, NDA, Vital capacity, Private Securities Litigation Reform Act, Analysis, Fibrosis, SAN, Partnership, Safety, Orphan, Primary sclerosing cholangitis, Nasdaq, Pharmacokinetics, Investigational New Drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND World's Fair Line, Mortality, IPF, European Medicines Agency, NASH, Therapy, COVID-19, Cirrhosis, Program, Financial condition report, ELF, Fast Track, Result, FDA, Biomarker, ALP, YouTube, IND, Achievement, Conversation, Review, Company, Twitter, Risk, LinkedIn, Pharmaceutical industry, Medical imaging, Novartis

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2022 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2022 financial results.
  • A highlight to our teams progress in 2022 is the positive safety and efficacy data from the INTEGRIS-IPF Phase 2a trial.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
  • For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Primary Sclerosing Cholangitis (PSC) Epidemiology and Market Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022
Biotechnology, Health, Other Health, Primary sclerosing cholangitis, Algorithm, Diagnosis, Technology, Clinical trial, Research, Acquisition, Awareness, PSC, News, Comprehension, Disease, Medical device, Management, Dentistry, Pharmaceutical industry, Epidemiology

This "Primary Sclerosing Cholangitis (PSC)- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Points: 
  • This "Primary Sclerosing Cholangitis (PSC)- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Primary Sclerosing Cholangitis (PSC) market report gives a thorough understanding of the Primary Sclerosing Cholangitis (PSC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
  • The Primary Sclerosing Cholangitis (PSC) epidemiology division provide insights about historical and current Primary Sclerosing Cholangitis (PSC) patient pool and forecasted trend for every seven major countries.
  • Drug chapter segment of the Primary Sclerosing Cholangitis (PSC) report encloses the detailed analysis of Primary Sclerosing Cholangitis (PSC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.